


## NCTN Head and Neck Cancer Trials Portfolio (Open as of 6/15/2025)


Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.



## **NCTN Head and Neck Cancer Trials Portfolio (Open as of 6/15/2025)**

Each far right box includes the NCTN protocol number with a hyperlink to the associated ClinicalTrials.gov webpage. Click on it to view the protocol title and study information.

### **Cross-disease trials:**



## NCTN Head and Neck Cancer Trials (Open as of 6/15/2025)

| Protocol Number  | Phase  | Protocol Title   |
|------------------|--------|--|
| <b>A092105</b>   | II     | Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy   |
| <b>A092205</b>   | III    | Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease  |
| <b>CCTG-HN11</b> | III    | SPECT-CT Guided Elective Contralateral Neck Treatment [SELECT] for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial   |
| <b>EA3132</b>    | II     | Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing  |
| <b>EA3161</b>    | II/III | A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA   |
| <b>EA3191</b>    | II     | A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features   |
| <b>EA3211</b>    | III    | Phase III Randomized Trial of Immunotherapy with or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma   |
| <b>EA3231</b>    | III    | A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em   |
| <b>NRG-HN006</b> | II/III | Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer   |
| <b>NRG-HN009</b> | II/III | Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m <sup>2</sup> ) Every Three Weeks Versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m <sup>2</sup> ) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)  |
| <b>NRG-HN010</b> | II     | A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable HER2-Positive Salivary Gland Cancer   |
| <b>NRG-HN011</b> | II     | A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)   |
| <b>RTOG-1216</b> | II/III | Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck   |
| <b>S2101</b>     | II     | Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study |
| <b>EAY191</b>    | Other  | Molecular Analysis for Combination Therapy Choice (ComboMATCH)   |
| <b>EAY191-A3</b> | II     | Palbociclib and Binimetinib in RAS-Mutant Cancers: A ComboMATCH Treatment Trial  |
| <b>EAY191-E5</b> | II     | A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial  |
| <b>EAY191-N5</b> | II     | A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors: A ComboMATCH Treatment Trial   |
| <b>EAY191-S3</b> | II     | Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial  |